Universal Ibogaine Provides Bi-Weekly Default Status Report Update

Calgary, AB — January 3, 2026 — Leads & Copy — Universal Ibogaine Inc. (TSXV:IBO), a life sciences company focused on medicalized ibogaine-centered addiction care, has released a bi-weekly default status report update.

The company initially announced on November 25, 2025, that it would delay filing its annual audited financial statements for the year ended July 31, 2025, along with its related management's discussion and analysis (MD&A), and the Chief Executive Officer and Chief Financial Officer certifications. The prescribed deadline was November 28, 2025.

The Alberta Securities Commission granted Universal Ibogaine a management cease trade order (MCTO) on December 4, 2025. The company is obligated to file bi-weekly default status reports during the MCTO period. Failure to file the required financial documents or the bi-weekly reports will lead to a general cease trade order.

Universal Ibogaine intends to file the required financial documents upon completion of the audit of the consolidated financial statements for the year ended July 31, 2025. The company intends to start the audit process soon, with the ultimate completion depending on the outcome of the company’s current restructuring process and any related TSXV regulatory approvals.

According to National Policy 12‑203 Management Cease Trade Orders (“NP 12-203”), the company reports that since its last news release of December 18, 2025:

There have been no material changes to the information in the prior news releases / Default Status Report that would reasonably be expected to be material to an investor.

The Company has fulfilled its stated intentions with respect to satisfying the provisions of the alternative information reporting guidelines under NP 12-203.

There has not been, nor is there anticipated to be, any specified default subsequent to the default which is the subject of the Default Announcement.

There is no other material information respecting the Company's affairs that has not been generally disclosed.

UI intends to comply with the alternative information guidelines set out in NP 12-203 by issuing bi-weekly default status reports, each in the form of a news release. The company will also continue to disclose any other material information concerning its affairs and ongoing business activities.

The company also provided an update on its current restructuring process, initially noted in news releases on October 28 and December 18, 2025.

Universal Ibogaine previously temporarily closed its Kelburn Recovery Centre (Kelburn”) addiction treatment operation, located near Winnipeg, Manitoba. The company continues to pursue various financing options, which may include the sale of all or a portion of the Kelburn property to a third party, subject to any relevant regulatory approvals.

The company is in the process of completing the terms of a Letter of Intent (LOI”) for a planned Sale, and will advise of the terms of such once finalized.

Following a potential sale, Universal Ibogaine plans to focus on its medical research business, specifically the effort to have Ibogaine approved for use under the company’s Clinical Trial Application, planned to be submitted to Health Canada after the restructuring is complete.

A portion of the proceeds from a sale are intended to complete the audit process for the required filings and to repay the company’s outstanding convertible debt balances (principal owing of $726,500), which recently matured.

Nick Karos, CEO
Universal Ibogaine Inc.
612-309-3527
Nick.Karos@universalibogaine.com

Source: Universal Ibogaine Inc.